The Global Cell Based Assays Market is poised for growth driven by increased R&D investments, rising demand for personalized ...

In the immuno-oncology field, scientists discover, test, and validate novel immunotherapeutic agents that leverage the human immune system to fight cancer, such as checkpoint inhibitors, vaccine-based ...

An ELRIG webinar has explored how cell-based screening supports drug discovery, from early target validation to advanced ...

Scientists use multi-day live cell assays to monitor cell growth, viability, and cytotoxicity when evaluating the effects of drug treatment. However, maintaining consistent cell health over time ...

Gregory Russotti is the Chief Technology and Manufacturing Officer at Century Therapeutics, a company developing iPSC-derived, allogeneic immune cell therapy products for hematology/oncology ...

Avance Biosciences opened its new Potency and Cell-Based Assay Center of Excellence, a purpose-built facility designed to expand and centralize the company’s capabilities in potency and functional ...

Potency assay development uses DoE and QbD to improve accuracy, consistency, and regulatory readiness in biologics testing.

Adherent cell assays have lagged behind in automation, slowing drug discovery. Semarion’s SemaCyte® microcarrier platform streamlines these workflows by making adherent cells assay-ready, improving ...

High-content screening combines automated microscopy and quantitative image analysis to measure complex cellular phenotypes ...

ViQi adds a new advisor to the team in support of focusing on bioprocessing in pharma, CDMOs, and CROs. ...the need for ...